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Remission of nephrotic range proteinuria in type I diabetes. The
present study assessed the extent to which remission of nephrotic-range
proteinuria occurred in patients with 'I)'pe I diabetes enrolled in the
Captopril Study, a placebo controlled multicenter clinical trial of captopril
therapy in diabetic nephropathy. Of the 409 patients recruited into the
Captopril Study, 108 had nephrotic-range proteinuria (a 3.5 g124 hr) at
entry in the Study (baseline). This group was the subject of the present
study. Remission of nephrotic-range proteinuria was defined as follows:
(1) Onset of the remission was taken as the date when proteinuria was first
noted to be  1.0 g124 hr. (2) The reduction in proteinuria had to be
sustained for a minimum of six months and until the end of the Captopril
Study. (3) During the remission, the average of all 24 hour proteinuria
measurements could not exceed 1.5 g. (4) Decline in renal function could
not explain the reduced proteinuria. That is, the patient's serum creatinine
during the entire period of observation in the Captopril Study had to
remain at less than a doubling of the baseline serum creatinine. Remission
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of nephrotic-range proteinuria occurred in 7 of 42 patients assigned to
captopril (16.7%, mean follow-up 3.4 0.8years) and in 1 of 66 patients
assigned to placebo (1.5%, mean follow-up 2.3 1.1 years; P = 0.005,
comparing remission rate in captopril vs. placebo-treated patients). For
those who achieved remission (Remission group), the mean baseline
versus final proteinuria was 5.0 2.0 versus 0.9 0.7 g124 hr (P < 0.01),
and the mean baseline versus final serum creatinine was 1.5 0.5 versus
1.6 0.5 mg/dl (P = NS). For those who did not achieve remission (No
remission group), the mean baseline versus final proteinuria was 6.2 2.6
versus 5.1 3.0 g/24 hr (P < 0.01), and baseline versus final serum
creatinine was 1.5 0.4 versus 3.2 2,2 mg/dl (P < 0.001). Glomerular
filtration rate (GFR) assessed by urinary iothalamate clearance was stable
within the Remission group but declined significantly within the No
remission group. During the Captopril Study, the Remission group did not
differ from the No remission group with respect to diastolic blood
pressure, glycohemoglobin level, or cholesterol level. However, mean
systolic blood pressure during the Captopril Study was lower in the
Remission group compared to the No remission group (126 8 vs. 140
13 mm Hg, P = 0.002). We conclude that long-term remission of
nephrotic-range proteinuria with stable or nearly stable serum creatinine
level is a realistic goal in Type I diabetes. Remission is significantly
associated with captopril therapy and with achieving a lower systolic blood
pressure.
It is widely believed that the onset of nephrotic-range protein-
uria in the diabetic heralds the onset of inexorable progression to
end-stage kidney failure [1]. This belief was tested in the NIH
multicenter, controlled trial of captopril therapy in patients with
Type I diabetes and nephropathy (the Captopril Study). The
Captopril Study provided an unprecedented opportunity to exam-
ine the outcome of Type I diabetics with nephrotic-range protein-
uria because of the large number of these patients enrolled (N =
108) and followed long term (median 2.7 years).
Methods
The present study is a subgroup analysis of patients recruited
into the Captopril Study who at entry into the Study (baseline)
had nephrotic-range proteinuria (24 hr proteinuria a than 3.5 g).
The Captopril Study was a prospective, double-masked, random-
ized clinical trial performed in 30 clinical centers with support by
a Clinical Coordinating Center, a Central Laboratory, and a
Biostatistical Coordinating Center. Entry criteria for the Capto-
pril Study were patients aged 18 to 49 years, who had the onset of
insulin-dependent diabetes before age 30, and had diabetes of at
least seven years duration. In addition, the patients were required
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to have 24 hour proteinuria  500 mg and diabetic retinopathy.
Patients with serum creatinine levels at baseline > 2.5 mg/dl were
excluded. Details of the inclusion and exclusion criteria of the
Captopril Study have been previously reported [21.
Patients accepted into the Captopril Study were randomized to
captopril 25 mg three times daily or an identical placebo three
times daily, as previously described [2]. Blood pressure goals were
to achieve: (1) seated office diastolic pressure < 90 mm Hg; (2)
seated office systolic blood pressure < 140 mm Hg, or if baseline
systolic blood pressure was  150 mm Hg, the goal was a decrease
of at least 10 mm Hg and a maximum systolic blood pressure of
160 mm Hg. These goals had to be achieved without the use of
calcium channel blockers or other angiotensin-converting enzyme
(ACE) inhibitors. Following randomization the patients were seen
at two weeks, one month, and every three months thereafter until
death, dialysis, or transplantation. The final status of patients with
respect to death, dialysis, or renal transplantation was determined
as of the date of administrative censoring on September 30, 1992.
Definitions used in the present study
Captopril Study patients with baseline nephrotic-range protein-
uria ( 3.5 g!24 hr) were categorized based on their final outcome
in the Captopril Study, as follows:
Remission of nephrotic-rangeproteinuria. Onset of the remission
was defined as the date when 24 hour proteinuria was first noted
to be 1 g. In addition the reduction in proteinuria had to be
sustained for at least six months and until the end of the Captopril
Study. During the period of remission the mean of all 24 hour
proteinuria values could not exceed 1.5 g. Finally, the remission of
nephrotic-range proteinuria could not be explained by decline in
renal function. That is, during the course of the Captopril Study
serum creatinine levels had to be maintained at less than a
doubling of the baseline serum creatinine level, which was the
primary study endpoint [2].
No remission of nephrotic-range proteinuria. This outcome was
defined as failure to reduce proteinuria, as described above and/or
failure to maintain serum creatinine at less than a doubling of
baseline levels.
Statistical analysis
The results were analyzed with the Statistical Analysis System
software [3]. Dichotomous baseline characteristics of the treat-
ment groups and the remission groups were compared with
Fisher's exact test [4]; continuous baseline characteristics and the
mean value of measurements over follow-up visits were compared
between the groups with Wilcoxon rank-sum test [5}. The change
from baseline to the last follow-up visit within a remission group
was assessed with Wilcoxon sign-rank tests [5]. The analyses
included all patients with nephrotic syndrome at randomization
with patients retained in their assigned treatment group regard-
less of their adherence to the treatment regimen. P value of less
than 0.05 was considered to indicate statistical significance; all
statistical tests were two-sided. Mean values are shown one
standard deviation.
Results
The 30 clinical centers of the Captopril Study entered 409
patients into the study between December, 1987, and October,
1990. Of the 409 patients entered into the Captopril Study, 108
had nephrotic-range proteinuria at baseline. The baseline clinical
Table 1. Baseline clinical characteristics of the patients in this study
who at baseline had nephrotic-range proteinuria and were then
randomly assigned to the placebo or captopril groups
Placebo groupa
(N=66) Captopril groupa(N=42)
Age 34.6 6.5 34.9 6.1
% Male 64 57
% Black 21 5
Body weight kg 75.8 17 72.6 14
Edema, % of group 52 50
Years of insulin therapy 20.5 5.4 19.7 6.0
Serum creatinine mgldl 1.5 0.4 1.6 0.4
Creatinine clearance ml! 72 34 68 38
mm
I-GFR m1/min' 70 33 59 31
Proteinuria g/24 hr 5.9 2.5 6.4 2.7
Glycohemoglobin % 12.3 3.3 12.5 3.5
(Normal up to 8%)
Serum cholesterol mg/dl 279 75 300 100
Serum albumin g!dl 3.3 0.5 3.3 0.5
Hematocrit % 38.1 5.9 37.6 4.9
Blood pressure mm Hg
Systolic 144 22 146 18
Diastolic 88 13 89 9
MAPC 107 14 108 11
Pulse beats/mm 83.0 11 85.9 9
a No significant differences were present at baseline between the
patients with nephrotic-range proteinuria assigned to placebo or captopril,
except for % black (P = 0.025) and I-GFR (P = 0.048)b Urinary iothalamate (I) clearance (GFR) was performed in 64 of the
placebo patients and 41 of the captopril patients at baseline
cMean arterial pressure = diastolicpressure + 1/3 (systolic pressure —
diastolic pressure)
characteristics of these patients according to assignment to the
placebo or captopril group are shown in Table 1. As can be seen,
the two groups were similar except that the percent of black
patients (P = 0.025), and the urinary iothalamate clearance (P =
0.048) were higher in the placebo group than in the captopril
group.
Table 2 shows the baseline data on the 108 patients according
to whether remission or no remission of nephrotic-range protein-
uria occurred during follow-up in the Captopril Study. As can be
seen, eight patients experienced remission, 100 patients did not.
Seven of the eight patients who achieved remission during the
Captopril Study had been assigned to captopril therapy. The
remission rate associated with captopril therapy (16.7%) was 11
times greater than that associated with placebo therapy (1.5%), P
= 0.005. Of the 16 black patients, none experienced remission of
nephrotic-range proteinuria (P = 0.602).
Figure 1 shows the sequential changes in proteinuria and Figure
2 shows the sequential changes in serum creatinine in each of the
eight Remission patients. As can be seen, each Remission patient
maintained stable or nearly stable serum creatinine levels as
proteinuria declined during the Captopril Study. The one patient
assigned to placebo who achieved remission also received ACE
inhibitor therapy for the majority of follow-up in the Captopril
Study. This occurred when the patient was removed from the
study protocol after 12 months because of inadequate control of
blood pressure. At that time therapy with an ACE inhibitor was
begun. This patient's course in relation to ACE inhibitor therapy
is shown in more detail in Figures 1 and 2.
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No
Remission
group,N=8
remission
group,N=100
Assignmenta
captopril 7 35
placebo 1 65
Age 34.1 5.4 34.7 6.5
% Male 62 61
% Black 0 16
Body weight kg 69.2 9.5 75,0 16.5
Edema, % of group 50 51
Years of insulin therapy 19.3 6.8 20.3 5.6
Serum creatinine mgldl 1.5 0.5 1.5 0.4
Creatinine clearance mi/mm 84 41 69 25
I-GFR 70 39 66 33
Proteinuria g/24 hr
Serum albumin gIdi'
5.0 2.0
3.6 0.7
6.2 2.6
3.2 0.5
Glycohemoglobin % 11.8 2.8 12.4 3.4
Serum cholesterol mgldl 330 200 284 71
Hematocrit % 37.9 6.4 37.9 5.5
Blood pressure mm Hg
systolic 135 25 145 20
diastolic 87 18 89 11
MAP 103±19 108±12
Pulse beats/mm 90 9 84 11
a P = 0.005 comparing frequency of remission of nephrotic syndrome,
during the Captopril Study, in captopril vs. placebo-treated patients. Five
patients (2 assigned to captopril, 3 assigned to placebo) had 3 months or
less follow-up in the Captopril Study. Baseline results for these patients
are not included in the No remission group.
bp = 0.048
Table 3 summarizes the average of all follow-up laboratory and
clinical parameters, and the final laboratory and clinical parame-
ters, in the Remission and No remission groups. Five of the 108
patients with nephrotic-range proteinuria at baseline were not
included in this analysis (2 assigned to captopril, 3 assigned to
placebo) because only three months or less of follow-up data were
available. For the eight patients who achieved remission, the
clinical and laboratory characteristics did not change significantly
from baseline (Table 2), except for proteinuria (P = 0.008) and
cholesterol (P = 0.039). Relative to baseline, final proteinuria
decreased by 4.1 2.4 g124 hr and cholesterol decreased by 127
184 mg/dl. For the 95 patients who did not achieve remission and
had at least three months of follow-up, all of the clinical and
laboratory characteristics changed signfficantly from baseline (Ta-
ble 2) except for glycosylated hemoglobin and systolic blood
pressure. Relative to baseline, body weight, serum albumin and
serum creatinine at the final visit increased while the clearance
measurements, proteinuria, cholesterol, hematocrit, diastolic
blood pressure and pulse rate decreased.
The distribution of the average of the sequential measurements
at follow-up visits was compared between the remission groups.
The average of the proteinuria measurements was significantly
lower in the Remission group, P < 0.001. In addition, compared
to the No remission group, the Remission group had significantly
higher serum albumin levels (P 0.001) and lower systolic blood
pressures (P 0.002).
Fig. 1. Sequential changes in 24-hour urine proteinuria in al/patients (N =
8) who achieved remission of nephrotic-range protemnuria in the Captopril
Study. The study drugs (captopril or placebo) were begun at 0 years. The
single patient assigned to placebo therapy is shown as a closed square. The
point at which ACE inhibition therapy was begun in this patient is shown
by an arrow.
To assess whether the relationship between treatment assign-
ment and remission was the result of a significantly greater
number of blacks assigned to placebo (N = 14)versus captopril (N
= 2),we evaluated the relationship between treatment assignment
and remission in the subgroup of 92 non-black patients. This
analysis showed that the remission rate associated with captopril
therapy (17.5%, 7 of 40) was nine times greater than the placebo
therapy remission rate (1.9%, 1/52), P = 0.019.
To assess whether differences in antihypertensive therapy, in
addition to captopril, could account for remission of nephrotic-
range proteinuria, we analyzed whether the use of diuretic, beta
blocker, or clonidine therapy during the Captopril Study differed
Table 2. Selected baseline characteristics of the patients who during
the Captopril Study either achieved remission of nephrotic range
proteinuria (Remission group) or did not achieve remission of
nephrotic-range proteinuria during the Captopril Study (No remission
group)
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Fig. 2. Sequential changes in semm creatinine in all patients (N = 8) who
achieved remission of nephrotic-rangeproteinuria during the Captopril Study.
The conventions used in this figure are the same as those of Figure 1.
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Follow-up years
Remission group(N=8) No-remission group(N=95)
3.4 0.8 2.3 1.1
All follow-up Final All follow-up Final
Body weight kg 68.0 10.2 68.0 10.1 75.4 16.6 75.8 17.1
Serum creatine 1.6 0.6 1.6 0.5 2.4 1.2 3.3 2.2a
mgldl
Clearance of 63 35 67 51 49 28 38 29'
creatinine mi/mm
I-GFR 59 39 39 28C
24 hr proteinuria g 1.6 0.8 0.9 0.7" 5.2 2.3 5.1 3.0
Serum albumin g/dl 4.0 0.4 4.0 0.5 3.3 0.5 3.4 0.6C
Glycohemoglobin % 11.5 1.8 11.4 2.0 12.5 2.9 12.3 3.2
Cholesterol mg/dl 242 85 203 29 259 61 238 64
Hematocrit % 37.5 5.5 36.9 3.7 36.1 5.6 34.0 6.9
Blood pressure
mm Hg
systolic 126 8g 119 7 140 13 143 23
diastolic 81 8 76 7 85 8 85 11
MAP 96 7" 90 7 104 8 104 13
Pulse rate per mm 81.1 9.8 83.5 20.8 82.2 9.2 81.2 10.5
a P < 0.001 compared to own baseline, P = 0.018 compared to other
group Final value
< 0.001 compared to own baseline, P = 0.048 compared to other
group Final value
P < 0.001 compared to own baseline (75 of 95 patients studied)dP < 0.008 compared to own baseline, P < 0.001 compared to other
group Final value
P = 0.004 compared to other group Final value
= 0.039 compared to own group baseline value
g P = 0.002 compared to other group Follow-up value
P = 0.013 compared to other group Follow-up value
between the Remission and No remission groups. No significant
differences of usage of these drugs was present, although there
was a trend for more prevalent use of diuretics (mainly furo-
semide) in the No remission group in which 77.9% received a
diuretic on 50% or more of scheduled visits. In the Remission
group 50% received diuretics on 50% or more of scheduled visits
(P = 0.095 comparing diuretic use in the Remission, No remission
groups).
Dietary protein intake assessed by measurement of 24 hour
urine urea excretion was not different between the Remission and
No remission groups at baseline (14.1 6.8 vs. 10.7 5.3 g/kg124
hr, P = 0.144) or during follow-up (9.9 3.2 vs. 9.4 3.7 g'kg/24
hr, P = 0.616).
Discussion
The present study demonstrates that patients with Type I
diabetes and nephrotic-range proteinuria do not necessarily inex-
orably progress to renal failure, as the current literature suggests.
Indeed, the present study demonstrates a relatively high rate of
remission of nephrotic-range proteinuria that is accompanied by
stable or nearly stable GFR over a mean follow-up period of 3.4
years (range 2.2 to 4.2 years).
The overall remission rate of nephrotic-range proteinuria in the
Captopril Study was 7.4% (8 of 108 patients). However, the
remission rate was 16.7% (7 of 42 patients) in those assigned to
captopril therapy and 1.5% (1 of 66 patients) for those assigned to
1
__________________
Decrease
proteinuria
Decrease 8 Decrease
glomerular tubular
injury injury
Decrease
GFR loss
Fig. 3. Possible interactions of hypertension, proteinuria, and GFR loss in
patients with glomerulopathy. The interactions are shown as numbered
arrows. It is proposed that arrows 1 through 4 represent primary effects of
the interactions. Arrows 5 through 9 represent secondary effects of the
interactions. The relative importance of these primary and secondary
effects are unknown.
placebo therapy. The remission rate for the captopril group was
significantly better than that of the placebo group (P 0.005).
The more favorable outcome in the captopril-treated patients
with nephrotic-range proteinuria is consistent with the overall
results of the Captopril Study [2]. That is, of the 409 patients
entered into the Captopril Study, 207 patients were randomized to
captopril and 202 patients were randomized to placebo therapy.
During the course of the Captopril Study, 25 patients in the
captopril group doubled their serum creatinine, compared to 43
patients in the placebo group (P = 0.007). It was also determined
that the more favorable renal outcomes in the patients receiving
captopril therapy could not be attributed to better blood pressure
control. Thus, it was concluded that captopril exerts a renopro-
tective effect in Type I diabetes that is independent of the effect of
captopril to lower blood pressure [21.
The patients in the present study who achieved remission of
nephrotic-range proteinuria and maintained stable renal function,
had significantly lower systolic blood pressure than those who did
not achieve remission of nephrotic-range proteinuria. There is
considerable evidence that control of blood pressure is important
in decreasing proteinuria in patients with diabetic glomeruloscie-
rosis [1, 6—8]. Thus, it is likely that at least some of the reduction
in proteinuria in the Remission group can be attributed to better
control of blood pressure in those receiving captopril therapy. On
the other hand, there is considerable evidence that, at the same
level of blood pressure control, ACE inhibitors are better at
reducing proteinuria in diabetic patients than are other classes of
antihypertensive agents [9]. Thus, it is also likely that at least some
of the effect of captopril therapy to induce remission of nephrotic-
range proteinuria, can be attributed to the fact that captopril is an
ACE inhibitor.
A detailed analysis of the interrelationships between blood
pressure, proteinuria, GFR loss, and its relevant covariates will be
the subject of a separate report. However, it is appropriate to
point out the complexities of these interrelationships (Fig. 3). We
Table 3. Summary of mean value of measurements at follow-up visits,
and the last follow-up visit in the Remission group compared to No
remission group
Decrease
hypertension
\5\2
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suggest that both blood pressure control and reduced proteinuria
contribute to the reduced rate of GFR loss in the Remission
group compared to the No remission group. Evidence that blood
pressure control may be a primary event (arrows 1 and 2) in
slowing the progression of diabetic microvascular disease is
suggested by the studies showing that the progression of diabetic
nephropathy is slowed by measures that improve control of blood
pressure [1, 6—8]. Evidence that reducing proteinuria may be a
primary event (arrows 3 and 4) in slowing progression of renal
disease is suggested by studies in experimental models of protein-
uria and studies in humans [10]. These studies indicate that
filtered proteins or substances accompanying the filtered proteins,
may cause injury to the glomerular mesangium or epithelium, or
to the renal tubules [11]. Nephrotoxic substances that are in-
creased in glomerular filtrate under proteinuric conditions include
the iron in transferrin, which may catalyze the formation of free
oxygen radicals [12], lipids or lipoproteins that may activate
inflammatory pathways [10], and components of the alternative
complement pathway which can be activated by proximal tubular
brush border [13]. Also, there is evidence in diabetics that the
extent to which proteinuria is reduced by improving blood pres-
sure control predicts the extent to which GFR decline is slowed
[14].
Reductions in proteinuria may also slow progression of diabetic
glomerulosclerosis because reducing proteinuria lowers plasma
lipoproteins that can promote glomerular injury [15—17]. Capto-
pril might also slow progression of diabetic glomerulosclerosis by
effects not directly related to its effect to decrease proteinuria and
decrease blood pressure. Recently it has been demonstrated that
angiotensin II formation, which is inhibited by captopril, stimu-
lates formation of TGF-13 which induces collagen formation [18,
19]. Angiotensin II is also a growth factor that could promote
glomerular hypertrophy, and its adverse effects on glomerular
structure [20]. Both of these effects would be inhibited by capto-
pril. Finally, captopril may have direct effects [21—24] or indirect
effects [25] on the glomerular filtration barrier that could reduce
proteinuria.
Previous studies do not show the high rates of remission of
nephrotic-range proteinuria in patients with Type I diabetes,
which are documented in the present study. However, the Cap-
topril Study represents, by far, the largest number of patients with
Type I diabetes and nephrotic-range proteinuria reported to date.
Also, the average duration of therapy in the Captopril Study
(median 2.7 years) is much longer than that of most previous
studies involving ACE inhibition in diabetic glomerulosclerosis [1,
6, 91. This is relevant because as demonstrated herein, the nadir
levels of proteinuria in those who experienced remission generally
occurred after one year of captopril therapy (Fig. 1).
The relatively high remission rate of nephrotic-range protein-
uria in the present study might also be related to better blood
pressure control achieved in the Remission group (mean fol-
low-up systolic and diastolic blood pressure 126 8 and 81 8
mm Hg, respectively) compared to the No remission group (mean
follow-up systolic and diastolic pressure 140 13 and 85 8 mm
Hg, respectively). These observations suggest that in patients with
diabetic glomerulosclerosis and nephrotic-range proteinuria, "hy-
per control" of blood pressure is important in slowing progression
of diabetic renal disease. However, as suggested in Figure 3,
decreased hypertension could also result from decreased glomer-
ular damage. Thus, the present findings do not differentiate the
effect of improved blood pressure control to lessen glomerular
damage from the effect of less glomerular damage to improve
blood pressure control.
Whether "hyper control" of blood pressure might cause harm
in patients with diabetic glomerulosclerosis Cannot be determined
from the present study. There is evidence that patients with
ischemic heart disease may be exposed to an increased risk of fatal
myocardial infarction if their diastolic blood pressure is consis-
tently reduced to less than 85 mm Hg [26]. In the Captopril Study
we did not identify instances where myocardial ischemia was
induced by achieving lower blood pressure levels. However, until
studies examining the risk/benefit ratio of "hyper control" of
blood pressure in patients with diabetic glomerulosclerosis are
completed, no firm recommendations regarding specific levels of
blood pressure control can be made.
Previous studies have demonstrated that reducing dietary pro-
tein intake in patients with diabetic glomerulosclerosis may re-
duce proteinuria and slow progression of renal disease [27] and
that ACE inhibitor therapy and reduced protein intake may have
additive beneficial effects on proteinuria [281. However, these
potential effects of diet cannot explain the present findings
because there was no difference in dietary protein intake between
the Remission and No remission groups during the Captopril
Study, based on measurement of 24-hour urine urea excretion.
In summary, remission of nephrotic-range proteinuria, while
maintaining stable or nearly stable renal function, is a realistic
goal in patients with Type I diabetes and nephropathy. Captopril
therapy and control of systolic blood pressure appear to be
important in achieving this goal.
Reprint requests to Lee A. Hebert, M.D., The Ohio State University!
Nephrology, 1654 Upham Dr., Room N210 Means Hall, Columbus, Ohio
43210-1228, USA.
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